학술논문

In vitro pharmacological profile of GLPG3667 suggests differentiation from the TYK2 inhibitors deucravacitinib and TAK-279 at their clinical dose regimens
Document Type
Journal
Source
JOURNAL OF CROHNS & COLITIS; JAN 2024, 18 pI423-pI423, 1p. Supplement: 1
Subject
Language
English
ISSN
18764479